Cell and Gene Therapy Theme +12.56%, Obsidian (OBX) +76.06%, Follow-through to Mid/Small Caps Is Key
PickStock AI Summary
- The pre-market focus is cell and gene therapy. The theme’s 5-day strength is +12.56%, ranking 5th among 100 themes.
- The main question is whether Obsidian Therapeutics, Inc. (OBX) leadership spreads to laggards after the open.
- This note is not a buy signal. It is a checklist at 08:40 to narrow the theme, to be rechecked with intraday news and flows.
TL;DR
- Pre-market theme: Cell and Gene Therapy
- 5-day theme average change: +12.56%, ranked 5th of 100 themes
- Recent leading mover: Obsidian Therapeutics, Inc. (OBX) +76.06%
Why watch cell and gene therapy before the open
The cell and gene therapy theme covers companies developing and commercializing treatments that edit genes or modify cells to treat disease. Key areas include CAR-T, gene editing, viral vectors, cell therapy manufacturing, and process technologies.
08:40 is a useful pre-order time to narrow focus. This write-up is a checklist, not a buy signal, to decide which news and flows to verify during the session.
Intraday points to check
- Maintain prior-day strength: Confirm whether related stocks stay stronger than the theme average after the open.
- Leader-to-laggard gap: Check if only the headline names rise, or if the move broadens to second and third tier names.
- News plus volume: Movements accompanied by volume are more meaningful than isolated gap ups.
Related stocks to watch
| Stock | Market | Current/Recent Change | Checkpoint |
|---|---|---|---|
| Amgen (AMGN) | NASDAQ | +0.45% | Investing and collaborating in viral vectors and gene therapy technologies linked to cell and gene therapy pipelines |
| Regeneron (REGN) | NASDAQ | +0.12% | Participates via gene therapy and gene delivery collaborations and pipeline assets |
| Gilead (GILD) | NASDAQ | +0.07% | Expanded cell therapy, notably CAR-T, by acquiring Kite Pharma |
| Sillajen (215600) | KOSDAQ | +0.00% | Holds oncolytic virus and immunotherapy platforms linked to gene delivery and oncoimmuno treatments |
| ToolGen (199800) | KOSDAQ | +0.00% | Holds CRISPR-based gene editing technology and related patents directly tied to gene therapy development |
| SK bioscience (302440) | KOSPI | +0.00% | Biologics development and CMO capabilities linking to gene and cell therapy manufacturing |
Risks
- If the theme already rallied sharply, the important factor is whether volume holds in pullback phases rather than chasing the initial gap.
- Early-session theme strength can change quickly, so check index direction, FX, and US futures as well.
- Monitor intraday recovery for relatively weak recent names (ToolGen (199800) -2.47% over the past 5 trading days).
Read more
- View cell and gene therapy stocks and leaders
- Market-wide flow today: PickStock Insight
- Expand the theme yourself: Mindmap
Published: 2026-08-13 08:40 KST. Data sources: PickStock theme DB, Yahoo Finance price cache. Generated automatically after outlier removal. For information purposes only, not investment advice.
관련 테마의 대표 기업을 확인하고, 내 관심 종목은 뉴스·시그널·시장 맥락으로 이어서 볼 수 있습니다.
종목명을 입력하면 재무, 뉴스, 시장 데이터를 정보 제공용 점검 리포트로 정리합니다.
관심 테마로 저장하면 마이페이지에서 다시 볼 수 있고, 강한 움직임이 생길 때 주간 테마 시그널과 연결해 확인할 수 있습니다.
